Ceftobiprole medocaril for the treatment of community-acquired pneumonia

Vicenç Falcó, Joaquin Burgos, Benito Almirante

Research output: Contribution to journalArticleResearch

13 Citations (Scopus)


© 2018, © 2018 Informa UK Limited, trading as Taylor & Francis Group. Introduction: Ceftobiprole is a novel broad-spectrum cephalosporin with excellent activity against a broad range of pathogens that are important in community-acquired pneumonia (CAP), including drug-resistant pneumococci, methicillin-resistant Staphylococcus aureus, and Pseudomonas aeruginosa. Areas covered: This article reviews the spectrum of activity, the main pharmacological and pharmacodynamic characteristics of ceftobiprole as well its clinical efficacy and safety in the treatment of CAP in adult patients. Expert opinion: Taking into account that the current treatment guidelines for CAP recommend the use of an adequate empirical therapy to improve its prognosis, ceftobiprole shows a profile of antimicrobial activity that would cover most etiological agents in patients with risk factors for infection caused by multidrug resistant organisms. The results of the pivotal clinical trial of patients hospitalized with CAP treated with ceftobiprole showed a high rate of clinical cure. The clinical tolerance of ceftobiprole in clinical trials was generally very good. These findings make ceftobiprole a good parenteral therapeutic alternative for the empirical treatment of CAP that requires hospitalization, especially in patients with risk factors for CAP caused by resistant microorganisms.
Original languageEnglish
Pages (from-to)1503-1509
JournalExpert Opinion on Pharmacotherapy
Publication statusPublished - 2 Sep 2018


  • Ceftobiprole
  • community-acquired pneumonia
  • methicillin-resistant Staphylococcus aureus pneumonia
  • Pseudomonas aeruginosa pneumonia


Dive into the research topics of 'Ceftobiprole medocaril for the treatment of community-acquired pneumonia'. Together they form a unique fingerprint.

Cite this